# Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers

> **NCT02526316** · PHASE1 · COMPLETED · sponsor: **Oryx GmbH & Co. KG** · enrollment: 11 (actual)

## Conditions studied

- HPV-induced Cancers

## Interventions

- **BIOLOGICAL:** P16_37-63 peptide combined with Montanide® ISA-51 VG
- **BIOLOGICAL:** P16_37-63 peptide without Montanide® ISA-51 VG

## Key facts

- **NCT ID:** NCT02526316
- **Lead sponsor:** Oryx GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526316, "Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02526316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*